Literature DB >> 28185422

The association of the HLA-A*24:02, B*39:01 and B*39:06 alleles with type 1 diabetes is restricted to specific HLA-DR/DQ haplotypes in Finns.

M-L Mikk1, T Heikkinen1, M I El-Amir1,2, M Kiviniemi1, A-P Laine1, T Härkönen3,4, R Veijola5, J Toppari6,7, M Knip3,4,8,9, J Ilonen1.   

Abstract

BACKGROUND: We analysed the previously reported association of the HLA-A*24:02, B*18 and B*39 alleles with type 1 diabetes and diabetes associated autoimmunity in the Finnish population applying HLA-DR/DQ stratification. MATERIALS &
METHODS: Haplotype transmission was analysed in 2424 nuclear families from the Finnish Paediatric Diabetes Register. Survival analysis was applied to study the development of islet autoantibodies and further progression to clinical diabetes in the prospective follow-up cohort from the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) Study. The subjects were genotyped for specific HLA class I alleles by sequence-specific hybridization using lanthanide labelled nucleotide probes.
RESULTS: The HLA-B*39:06 allele was found almost exclusively on the (DR8)-DQB1*04 haplotype in which its presence changed the disease risk status of the whole haplotype from neutral to predisposing. The HLA-A*24:02 and the B*39:01 alleles increased the diabetes-associated risk of the DRB1*04:04-DQA1*03-DQB1*03:02 haplotype but the alleles were in linkage disequilibrium and no independent effect could be detected. Within the DIPP cohort, neither the A*24:02 nor the B*39:01 allele were associated with seroconversion but were in contrast associated with increased progression from seroconversion to clinical disease. DISCUSSION &
CONCLUSIONS: The independent predisposing effect of the HLA-B*39:06 allele with type 1 diabetes was confirmed in the Finnish population but the association of the A*24:02 and B*39:01 alleles remained inconclusive whilst both A*24:02 and B*39:01 affected the progression rate from seroconversion to autoantibody positivity to overt type 1 diabetes.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990HLA haplotypes; HLA-A*24; HLA-B*18; HLA-B*39; association study; seroconversion; type 1 diabetes

Mesh:

Substances:

Year:  2017        PMID: 28185422     DOI: 10.1111/tan.12967

Source DB:  PubMed          Journal:  HLA        ISSN: 2059-2302            Impact factor:   4.513


  8 in total

1.  HLA-B*39:06 Efficiently Mediates Type 1 Diabetes in a Mouse Model Incorporating Reduced Thymic Insulin Expression.

Authors:  Jennifer Schloss; Riyasat Ali; Jeremy J Racine; Harold D Chapman; David V Serreze; Teresa P DiLorenzo
Journal:  J Immunol       Date:  2018-04-09       Impact factor: 5.422

2.  Improved Murine MHC-Deficient HLA Transgenic NOD Mouse Models for Type 1 Diabetes Therapy Development.

Authors:  Jeremy J Racine; Isabel Stewart; Jeremy Ratiu; Greg Christianson; Emily Lowell; Kelsay Helm; Jennifer Allocco; Richard S Maser; Yi-Guang Chen; Cathleen M Lutz; Derry Roopenian; Jennifer Schloss; Teresa P DiLorenzo; David V Serreze
Journal:  Diabetes       Date:  2018-02-22       Impact factor: 9.461

3.  NMR-based metabolomics characterizes metabolic changes in different brain regions of streptozotocin-induced diabetic mice with cognitive decline.

Authors:  Tingting Zhang; Hong Zheng; Kai Fan; Nengzhi Xia; Jiance Li; Changwei Yang; Hongchang Gao; Yunjun Yang
Journal:  Metab Brain Dis       Date:  2020-07-08       Impact factor: 3.584

4.  The serum concentration of βCGRP is novel marker for type 1 diabetes.

Authors:  Yong Chen; Yunfeng Lin; Jingwen Wang; Xinxin Guo; Yujia Guo; Feng Dong; Feng Gao; Qicai Liu
Journal:  Heliyon       Date:  2020-01-16

5.  Non-HLA Gene Polymorphisms in the Pathogenesis of Type 1 Diabetes: Phase and Endotype Specific Effects.

Authors:  Antti-Pekka Laine; Milla Valta; Jorma Toppari; Mikael Knip; Riitta Veijola; Jorma Ilonen; Johanna Lempainen
Journal:  Front Immunol       Date:  2022-06-21       Impact factor: 8.786

6.  Development and validation of a prognostic model for kidney function 1 year after combined pancreas and kidney transplantation using pre-transplant donor and recipient variables.

Authors:  Katharina S Zorn; Simon Littbarski; Ysabell Schwager; Alexander Kaltenborn; Jan Beneke; Jill Gwiasda; Thomas Becker; Felix Braun; Benedikt Reichert; Jürgen Klempnauer; Harald Schrem
Journal:  Langenbecks Arch Surg       Date:  2018-10-18       Impact factor: 3.445

7.  Circulating β cell-specific CD8+ T cells restricted by high-risk HLA class I molecules show antigen experience in children with and at risk of type 1 diabetes.

Authors:  L Yeo; I Pujol-Autonell; R Baptista; M Eichmann; D Kronenberg-Versteeg; S Heck; G Dolton; A K Sewell; T Härkönen; M-L Mikk; J Toppari; R Veijola; M Knip; J Ilonen; M Peakman
Journal:  Clin Exp Immunol       Date:  2019-11-10       Impact factor: 4.330

8.  SARS-CoV-2 transcriptome analysis and molecular cataloguing of immunodominant epitopes for multi-epitope based vaccine design.

Authors:  Sandeep Kumar Kushwaha; Veerbhan Kesarwani; Samraggi Choudhury; Sonu Gandhi; Shailesh Sharma
Journal:  Genomics       Date:  2020-09-10       Impact factor: 5.736

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.